Overview
- A published case report describes an elderly woman with advanced Alzheimer’s who, after a supervised 5‑gram dose of psilocybin mushrooms, awoke from a long sleep‑like state and spoke for several hours before showing multi‑day gains in alertness, walking, dressing, emotional reciprocity and urinary continence.
- The team reports the patient remained continent one month after the first session and received a supervised 3‑gram follow‑up, but they emphasize these are single‑patient observations made in a private clinical setting without brain imaging, biomarkers, or standardized cognitive testing.
- The acute drug response included strong autonomic activation with profuse sweating and suspected hyperthermia, showing that high doses can pose serious medical risks for frail, older adults with neurologic disease.
- Authors propose a mechanism in which psilocybin’s action at 5‑HT2A receptors alters large‑scale network dynamics and may temporarily reintegrate residual function, yet they stress causality is unproven and alternative explanations cannot be excluded.
- Researchers and commentators say the case is hypothesis‑generating and that rigorous trials are needed with objective outcome measures, physiological monitoring, biomarker confirmation of Alzheimer’s pathology, control groups, and explicit ethical oversight to assess safety and efficacy.